The Goldman Sachs Group, Inc. (NYSE:GS) joined JPMorgan in pulling down its forecasts for U.S. Treasury yields

The Goldman Sachs Group, Inc. (NYSE:GS) joined JPMorgan Chase & Co. in pulling down its forecasts for U.S. Treasury yields, incorporating expectations for a prolonged hit from the U.S.-China trade war, along with the dovish shift by key central banks. Goldman’s strategists slashed their year-end 10-year U.S. yield call to 1.75% — matching JPMorgan’s updated prediction from May 31. That’s down from Goldman’s 2.80% projection reiterated last Sunday. Goldman also cut its yield forecasts for Japan, the euro region and other developed nations.

The Goldman Sachs Group, Inc. (NYSE:GS)’s stock on Wednesday traded at beginning with a price of $196.50 and when day-trade ended the stock finally gained 0.48% to reach at $197.01. Analyst’s mean target price for GS is $230.76 while analysts mean recommendation is 2.50. Stock value has moved between $151.55 – 246.26 in last one year. 

Analyst’s ratings determines the future of any company. Stock has got OUTPERFORM rating from 6 analyst(s) whereas last month 5 analyst(s) have given outperform rating. SELL rating has been given by 1 analyst(s) and 5 analyst(s) given BUY rating to the stock. Company fiscal year is ending in December and analysts’ consensus recommendation is outperform for GS and estimated EPS for next quarter is 5.33. 

The Goldman Sachs Group, Inc. (NYSE:GS) yearly performance is -11.07% and net profit margin is 17.50%. Annual EPS Growth of past 5 years is 9.20%. The current share price indicates that stock is -19.61% away from its one year high and is moving 29.87% ahead of its 52-week low. 



On 26 June 2018, Teva Pharmaceutical Industries Limited (NYSE:TEVA) stock price started the day at $8.81 and moved between $8.97-$8.59 to finally close at $8.89. TEVA’s distance from 20 day simple moving average is 0.95% and distance from 50-Day simple moving average is -23.79%. In last 4 months performance of TEVA was -44.44% while its price to sale ratio is 0.53 and price to book ratio is 0.66. 

Analysts expect Teva Pharmaceutical Industries Limited (NYSE:TEVA) to report 0.57 EPS and has got OUTPERFORM rating from 3 of Thomson Reuters analysts and 3 analyst(s) given UNDERPERFORM rating. Analyst’s mean target price for TEVA is $16.48 while analysts mean recommendation is 2.80. Firm LT growth rate is estimated as 4%. 



V.F. Corporation (NYSE:VFC)’s stock on Wednesday traded at beginning with a price of $85.66 and when day-trade ended the stock finally gained 0.34% to reach at $85.70. Analyst’s mean target price for VFC is $95.41 while analysts mean recommendation is 2.00. Stock value has moved between $63.01 – 91.17 in last one year. 

Stock has got OUTPERFORM rating from 10 analyst(s) whereas last month 10 analyst(s) have given outperform rating. SELL rating has been given by 0 analyst(s) and 7 analyst(s) given BUY rating to the stock. Company fiscal year is ending in March and analysts’ consensus recommendation is outperform for VFC and estimated EPS for next quarter is 1.29. 

V.F. Corporation (NYSE:VFC) yearly performance is 12.12% and net profit margin is 9.10%. Annual EPS Growth of past 5 years is 1.40%. The current share price indicates that stock is -6.13% away from its one year high and is moving 35.54% ahead of its 52-week low. 

Leave a Reply